bupivacaine + clonidine + morphine

This is a combination of three drugs—bupivacaine, clonidine, and morphine—administered together, most commonly via the intrathecal or epidural route for the management of severe pain. - **Bupivacaine** is a long-acting local anesthetic that blocks voltage-gated sodium channels in nerve cells, inhibiting nerve impulse transmission and providing regional anesthesia. - **Clonidine** is an alpha-2 adrenergic receptor agonist that enhances analgesia by inhibiting nociceptive neuron firing in the dorsal horn of the spinal cord and reducing sympathetic outflow. - **Morphine** is an opioid receptor agonist (primarily at mu-opioid receptors), producing potent analgesia by modulating pain signaling pathways in both the central and peripheral nervous systems. The combination leverages synergistic effects among these agents to provide superior analgesia compared to monotherapy or dual combinations. Clinical studies have shown that this triple therapy can improve pain control, reduce opioid consumption, blunt opioid dose escalation over time, and may increase the therapeutic window for antinociception without proportionally increasing side effects[1][2][3][4]. This regimen is used primarily for chronic or refractory pain (including cancer-related or terminal conditions) when other treatments are insufficient.

Other names

intrathecal analgesiaIT analgesiaintrathecal bupivacaine, morphine, and clonidine